FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 8, 2026 84 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POTOMAC study Source RELATED ARTICLESMORE FROM AUTHOR Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab MOST POPULAR What Is Peripheral Neuropathy and How Can It Be Prevented or... July 14, 2020 The US National COVID Cohort Collaborative Consortium Provides Real-World Evidence on... March 29, 2022 Countdown to 100,000 OncoLife Survivorship Care Plans: What is a Survivorship... February 25, 2021 Sisters on Opposite Sides of the Country Diagnosed with Breast Cancer... December 16, 2020 Load more HOT NEWS Atlantic rowing trio smash world record and raise thousands for cancer... Volunteering with Pride: Brett’s award-winning involvement with Cancer Research UK FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell... ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers...
